KFDA approves Novartis's osteoporosis drug

Novartis Korea said on October 16 that the Korea Food and Drug Administration has approved its osteoporosis medicine Aclasta (zoledronic acid 5 mg) for treatment of women with postmenopausal osteoporosis.

A once-yearly infusion of Aclasta significantly reduced the incidence of all types of bone fractures over three years in women with postmenopausal osteoporosis. These results, published in...